Logo de VHL
Logo de BIGG Rec
Resultados: 1 - 10 de 1,823

(Screening and treatment of cervical pre-cancer lesions for cervical cancer prevention: use of human papillomavirus (HPV) DNA genotyping) Recommendations for the general population of women. Regardless of follow-up capacity If a programme provides triage with additional tests, WHO suggests using visual inspection with acetic acid (VIA) or colposcopic impression (without histological confirmation) as the triage test rather than cytology or dual-stain cytology.

Año
2026
Institución
World Health Organization

Recomendado a favor

Condicional

Recommendations for the general population of women . In settings with high follow-up capacity (60% or greater) and sufficient ablative treatment capacity, WHO suggests using HPV DNA testing with extended or limited genotyping OVER treating all HPV-positive women or triaging all HPV-positive women with additional tests. In settings with high follow-up capacity (60% or greater) and sufficient ablative treatment capacity where HPV DNA extended genotyping is used, WHO suggests: • treating all eligible women with ablative treatment who test positive for carcinogenic HPV (cHPV) types 16 (group 1a), 18 and 45 (group 1b) and 31, 33, 35, 52 and 58 (group 1c); AND triaging women who test positive for cHPV types 39, 51, 56 and 59 (group 1d); OVER • treating all eligible women with ablative treatment who test positive for cHPV types 16 (group 1a), 18 and 45 (group 1b), AND triaging women who test positive for cHPV types 31, 33, 35, 52, 58, 39, 51, 56 and 59 (groups 1c and 1d); OVER • treating all eligible women with ablative treatment who test positive for cHPV types 16 (group 1a), 18 and 45 (group 1b) AND triaging women who test positive for cHPV types 31, 33, 35, 52 and 58 (group 1c) AND returning women who test positive for cHPV types 39, 51, 56 and 59 (group 1d) to routine screening.

Año
2026
Institución
World Health Organization

Recomendado a favor

Condicional

Recommendations for the general population of women . In settings with low follow-up capacity (less than 60%) and sufficient ablative treatment capacity, WHO suggests: • treating all eligible women with ablative treatment who test positive for any carcinogenic HPV (cHPV) types 16 (group 1a), 18 and 45 (group 1b), 31, 33, 35, 52 and 58 (group 1c), 39, 51, 56 and 59 (group 1d), consistent with a no-genotyping approach; • OR treating eligible women with ablative treatment who test positive for any cHPV types 16 (group 1a), 18 and 45 (group 1b) and 31, 33, 35, 52 and 58 (group 1c) [This can be done using an 8-cHPV type test (tests designed to detect the eight most cHPV types) as per WHO target product profiles for HPV screening tests, or when using extended genotyping HPV tests.] OVER • treating all eligible women with ablative treatment who test positive for cHPV types 16 (group 1a), 18 and 45 (group 1b) AND triaging women who test positive for cHPV types 31, 33, 35, 52, 58, 39, 51, 56 and 59 (groups 1c and 1d); or OVER • triaging with additional tests all women who test positive for any cHPV types (1a, 1b, 1c and 1d).

Año
2026
Institución
World Health Organization

Recomendado a favor

Condicional

[Immunization to protect infants against respiratory syncytial virus disease]. For countries deciding to use a long-acting monoclonal antibody as the primary preventive strategy, WHO recommends a single dose at birth, or at the earliest opportunity thereafter if year-round administration is adopted. In a seasonal approach, administration of a single dose of a long-acting monoclonal antibody is recommended for infants and should begin shortly before the start of the RSV season, as well as at birth or the earliest opportunity thereafter for infants born during the RSV season

Año
2025
Institución
World Health Organization

Recomendado

El catéter uterino con globo se recomienda para el tratamiento de la hemorragia posparto debida a la atonía uterina después del parto vaginal en las mujeres que no responden al tratamiento estándar de primera línea, siempre que se pueda recurrir de forma inmediata, de ser necesario, a la intervención quirúrgica y a los hemoderivados. Se encuentra disponible y se aplica habitualmente un protocolo principal para el tratamiento de primera línea de las hemorragias posparto (incluso el uso de uterotónicos, ácido tranexámico, líquidos intravenosos). Otras causas de la hemorragia posparto (como la retención de los tejidos placentarios y los traumatismos) pueden excluirse de manera razonable. El procedimiento es realizado por el personal de salud que se capacita y están calificados en el tratamiento de la hemorragia posparto, incluso en el uso del catéter uterino con globo. Las afecciones maternas se pueden controlar regularmente y adecuadamente para identificar de forma inmediata los signos de deterioro.

Año
2025
Institución
World Health Organization

Recomendación específica de contexto

Solo en contextos específicos